Ángel Baldán, Ph.D.
Studies on sterol homeostasis and the molecular mechanisms involved in the conversion of macrophages to foam cells.
Office: DRC, Room 615
Voice: (314) 977-9227
Ph.D., 2002, University of Barcelona
Our laboratory is interested in sterol homeostasis and in the molecular mechanisms involved in the conversion of macrophages into foam cells. This latter process is particularly relevant in several human pathologies, including atherosclerosis and different pulmonary lipidosis syndromes.
- CIDEC/Fsp27 is regulated by PPARα and plays a critical role in fasting- and diet-induced hepatosteatosis.
Langhi C, Baldán A. Hepatology. (2014) Nov 21 [Epub ahead of print}.
- ABCG1 is required for pulmonary B-1 B cell and natural antibody homeostasis.
Baldán A, Gonen A, et al. J Immunol. (2014) 193(11):5637-5648.
- Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice.
Goedeke L, Salerno A, et al. EMBO Mol Med. (2014) 6(9):1133-1141.
- Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte.
Langhi C, Marquart TJ, et al. J Hepatol. (2014) 61(2):358-365.
- Control of very low-denisty lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33.
Allen RM, Marquart TJ, et al. Circ Res. (2014) 115(1):10-22.
- MicroRNAs and cardiovascular disease.
Fernandez-Hernando C, Baldán A. Curr Genet Med Rep. (2013) 1(1):30-380.
- Quest for new biomarkers in atherosclerosis.
Cho Y, Baldán A. Mo Med. (2013) 110(4):325-330.
- Impaired liver regeneration in Ldlr-/- mice is associated with an altered hepatic profile of cytokines, growth factors and lipids.
Pauta M, Rotllan N, et al. J Heptaol. (2013) 59(4):731-737.
- Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration.
Sene A, Khan AA, et al. Cell Metab. (2013) 17(4):549-61.
- MicroRNA-144 regulates hepatic ABCA1 and plasma HDL following activation of the nuclear receptor FXR.
de Aguiar Vallim T, Tarling E, et al. Circ Res. (2013) 112(12):1602-1612.
- Anti-miR-22 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Marquart TJ, Wu J, et al. Arterioscler Thromb Vasc Biol. (2013) 33(3):455-8.